Bukwang Pharm - Asset Resilience Ratio

Latest as of September 2025: 39.75%

Bukwang Pharm (003000) has an Asset Resilience Ratio of 39.75% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 003000 total debt and obligations for a breakdown of total debt and financial obligations.

Liquid Assets

₩188.03 Billion
≈ $127.42 Million USD Cash + Short-term Investments

Total Assets

₩472.99 Billion
≈ $320.54 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2007–2024)

This chart shows how Bukwang Pharm's Asset Resilience Ratio has changed over time. See 003000 net asset value for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Bukwang Pharm's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 003000 market cap overview.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩188.03 Billion 39.75%
Total Liquid Assets ₩188.03 Billion 39.75%

Asset Resilience Insights

  • Very High Liquidity: Bukwang Pharm maintains exceptional liquid asset reserves at 39.75% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Bukwang Pharm Industry Peers by Asset Resilience Ratio

Compare Bukwang Pharm's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Changchun High & New Technology Industries Group Inc
SHE:000661
Drug Manufacturers - Specialty & Generic 3.73%
Yuhan Corp.
KO:000100
Drug Manufacturers - Specialty & Generic 0.99%
Tasly Pharmaceutical Group Co Ltd
SHG:600535
Drug Manufacturers - Specialty & Generic 9.09%
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
Drug Manufacturers - Specialty & Generic 0.02%
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
Drug Manufacturers - Specialty & Generic 0.01%
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
Drug Manufacturers - Specialty & Generic 26.36%
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
Drug Manufacturers - Specialty & Generic 0.29%
Cronos Group Inc
TO:CRON
Drug Manufacturers - Specialty & Generic 69.94%

Annual Asset Resilience Ratio for Bukwang Pharm (2007–2024)

The table below shows the annual Asset Resilience Ratio data for Bukwang Pharm.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 10.72% ₩40.00 Billion
≈ $27.11 Million
₩373.18 Billion
≈ $252.90 Million
+10.34pp
2021-12-31 0.38% ₩1.50 Billion
≈ $1.02 Million
₩397.42 Billion
≈ $269.32 Million
-2.19pp
2020-12-31 2.57% ₩10.30 Billion
≈ $6.98 Million
₩400.97 Billion
≈ $271.73 Million
-3.95pp
2014-12-31 6.51% ₩15.43 Billion
≈ $10.46 Million
₩236.82 Billion
≈ $160.49 Million
-2.28pp
2013-12-31 8.79% ₩20.07 Billion
≈ $13.60 Million
₩228.21 Billion
≈ $154.66 Million
+3.73pp
2008-12-31 5.06% ₩11.67 Billion
≈ $7.91 Million
₩230.55 Billion
≈ $156.24 Million
-8.07pp
2007-12-31 13.13% ₩28.24 Billion
≈ $19.14 Million
₩215.02 Billion
≈ $145.71 Million
--
pp = percentage points

About Bukwang Pharm

KO:003000 Korea Drug Manufacturers - Specialty & Generic
Market Cap
$422.58 Million
₩623.56 Billion KRW
Market Cap Rank
#13412 Global
#449 in Korea
Share Price
₩6320.00
Change (1 day)
-3.95%
52-Week Range
₩3225.00 - ₩9600.00
All Time High
₩36947.85
About

Bukwang Pharmaceutical Co., Ltd. develops, produces, and sells pharmaceutical products in South Korea and internationally. It offers its products in oral solid dosage forms, injections, oral solutions, external solutions, and ointments. The company also provides ethical drugs, including drugs for treating diabetic peripheral neuropathy, hypothyroidism, toxic liver disease, chronic hepatitis, live… Read more